

# ARTRYA<sup>®</sup>

(ASX: AYA)

## Bell Potter Healthcare Conference


Company Presentation

20 November 2025

Not for Release to U.S. wire services or distribution in the United States



Reshaping the  
Future of  
Heart Care



# Important Notice

## IMPORTANT NOTICE AND DISCLAIMER

These presentation materials have been prepared by Artrya Limited (**Artrya** or **Company**). By receiving the Presentation Materials, you acknowledge and represent to the Company that you have read, understood and accepted the terms of this disclaimer. You must read this important notice before you attempt to access the Presentation Materials. The information on this page is not part of the Presentation Materials. If you do not understand it, you should consult your professional adviser without delay.

## NOT AN OFFER

These Presentation Materials are for information purposes only. The Presentation Materials do not comprise a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or any other law.

The Presentation Materials also do not constitute or form part of any invitation, offer for sale or subscription or any solicitation for any offer to buy or subscribe for any securities nor shall they or any part of them form the basis of or be relied upon in connection therewith or act as any inducement to enter into any contract or commitment with respect to securities. In particular, these Presentation Materials do not constitute an offer to sell or a solicitation to buy, securities in the United States of America. In particular, these Presentation Materials may not be released to U.S. wire services or distributed publicly in the United States.

These Presentation Materials have been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. These Presentation Materials do not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in these Presentation Materials have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable U.S. state securities laws.

The distribution of these Presentation Materials in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. By accepting this document, you represent and warrant that you are entitled to receive such presentation in accordance with the above restrictions and agree to be bound by the limitations contained therein. For further information, see the section titled "International Offer Restrictions".

## NOT INVESTMENT ADVICE

The Presentation Materials are not investment or financial product advice (nor tax, accounting or legal advice) and are not intended to be used for the basis of making an investment decision. Recipients should obtain their own advice before making any investment decision.

## SUMMARY INFORMATION

The Presentation Materials do not purport to be all inclusive or to contain all information about the Company or any of the assets, current or future, of the Company.

**THIS PRESENTATION HAS BEEN APPROVED FOR RELEASE BY THE BOARD OF ARTRYA LIMITED**

The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the Presentation Materials. The information in the Presentation Materials is of a general nature and does not purport to contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement or other offering document prepared in accordance with the requirements of Australian law or the laws of any other jurisdiction, including the United States of America.

The Company does not undertake to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

## FORWARD LOOKING STATEMENTS

Certain statements contained in the Presentation Materials, including information as to the future financial or operating performance of the Company and its business operations, are forward looking statements. Such forward looking statements:

- are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies;
- involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward-looking statements; and may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results and capital expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social and other conditions.

The Company disclaims any intent or obligation to publicly update any forward-looking statements, whether as a result of new information, future events or results or otherwise.

The words "believe", "expect", "anticipate", "indicate", "contemplate", "target", "plan", "intends", "continue", "budget", "estimate", "may", "will", "schedule" and similar expressions identify forward looking statements.

All forward looking statements contained in the Presentation Materials are qualified by the foregoing cautionary statements. Recipients are cautioned that forward looking statements are not guarantees of future performance and accordingly recipients are cautioned not to put undue reliance on forward looking statements due to the inherent uncertainty therein.

## NO LIABILITY

The Company has prepared the Presentation Materials based on information available to it at the time of preparation. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information, opinions and conclusions contained in the Presentation Materials. To the maximum extent permitted by law, the Company, its related bodies corporate (as that term is defined in the *Corporations Act 2001* (Cth) (**Corporations Act**)) and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including, without limitation, any liability arising from fault or negligence on the part of any person, for any loss arising from the use of the Presentation Materials or its contents or otherwise arising in connection with it.

# Artrya at a Glance

Salix® is the only real-time, point of care platform globally delivering end-to-end CCTA assessment



## Solution for Coronary Artery Disease

- Market cap ~AU\$550m
- Targeting a US\$4.4B<sup>1</sup> Cardiac CT market.



## Core Platform

- FDA-cleared
- Delivers real-time Cardiac CT reporting (~10 minutes) in existing workflows.



## Innovative Roadmap

- Plaque module FDA cleared
- Blood-flow module in FDA process
- Whole heart module increases revenue opportunity and TAM.



## U.S. Market Traction

Foundation customers live in the U.S., generating revenue, with a growing pipeline.

# Artrya's attractive market and model

Large Cardiac CT opportunity, a differentiated real-time platform, and a scalable health-system model.

## Attractive Market

**\$5Bn<sup>1</sup>**

Market Size

**> 6%**

YoY Growth

## Scalable Model

- Targeted U.S. GTM
- Long-term contracts
- Attractive unit economics
- Strong balance sheet

## Differentiated Product

- Unified AI and Reporting Platform
- Real-time CCTA report, Plaque, and FFRCT<sup>2</sup> analysis for faster diagnosis
- Patented cardiac CT platform

**Backed by Leading  
Institutional Investors:**

REGAL  
FUNDS MANAGEMENT

PARADICE  
INVESTMENT MANAGEMENT

Wilson  
Asset Management

# Current methods for diagnosing coronary artery disease are outdated

A point of care solution for rapidly diagnosing high risk plaque is a holy grail for clinicians



## Ineffective

Old methods ineffective in **detecting high-risk plaque**<sup>1</sup>




## Avoidable

**55% of invasive procedures are unnecessary**<sup>2,3,4</sup>




## Slow & Costly

Outdated methods are time consuming and higher cost to deliver



## Poor Control


Current solutions do not allow for **real-time and point-of-care** management



1. Comprehensive plaque assessment by coronary CT angiography. Nat Rev Cardiol 11, 390–402 (2014)
2. Low Diagnostic Yield of Elective Coronary Angiography. New England Journal of Medicine. March 11, 2010.
3. Temporal Trends in the Frequency of Inducible Myocardial Ischemia During Cardiac Stress Testing. Journal of the American College of Cardiology (JACC). March 12, 2013.
4. Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. JACC. March 2017

# Salix<sup>®</sup> provides streamlined, real-time patient assessment

Clear clinical insights into actionable decisions in minutes



## Point of care enabling real-time analysis – without humans

CCTA analysis in under 10 mins without human intervention.

## Detailed Plaque and Flow Analysis

Real-time assessment of plaque and FFRCT\* for improved treatment.

## Unified Reporting Platform

Consolidates all CCTA reporting into a single platform.



## Enhanced profitability for health systems

Transforms CCTA into a profitable modality and reduces costs by replacing multiple tools and vendors

\* Salix Coronary Flow not yet cleared by FDA

# From off-site workflows to 10-minute decision

Salix® fits directly into the existing clinical workflow; no uploads, no portals, no off-site vendors



# Coronary artery disease is a large and growing health challenge

Cardiovascular Disease Costs will Exceed \$1 Trillion by 2035 - American Heart Association<sup>4</sup>


## US\$4.4 billion\*

Serviceable Addressable Market (US)

U.S. patients undergoing CCTA + Plaque Assessment

### Tailwinds impacting TAM growth

- **Guideline Support** – AHA/ACC recommend CCTA as a first-line diagnostic for patients with chest pain<sup>5</sup>.
- **Attractive reimbursement – Category I CPT codes** support CCTA, plaque assessment, and FFRCT<sup>3</sup>.
- **CT-First Adoption** – Strong shift from invasive angiography and SPECT toward **non-invasive CT-based pathways**.



**6.2% YOY**  
Projected growth in Cardiac CCTA scans to 2028<sup>1</sup>

#### \* Assumptions


- National Average Medicare Rate
  - Reimbursement for Automated Plaque – US\$950 (CPT 0625T<sup>3</sup>)
  - Reimbursement for FFRCT – US\$1,017 (CPT 75580<sup>3</sup>)
- TAM estimated as total of all scans receiving Plaque reimbursement only
- FFRCT procedures have not been included in TAM

1 <https://www.dicardiology.com/article/rising-demand-cardiac-ct-positions-market-major-growth>  
2 Frost & Sullivan Analysis – Artrya Prospectus – <https://wcsecure.weblink.com.au/pdf/AYA/02456983.pdf>  
3 <https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta>  
4 Cardiovascular Disease: A Costly Burden for America – Projections Through 2035. American Heart Association.  
5 American College of Cardiology – 2021 AHA/ACC Chest Pain Guideline Perspectives

# Salix<sup>®</sup> is a single platform solution built to scale

Modular software powering complete, scalable CCTA analysis for coronary artery disease.

Increasing clinical utility & revenue opportunity



# Salix<sup>®</sup> platform successfully launched in the U.S.

Tanner Health collaboration partnership to validate and integrate



## Integrated and Live from July 2025

- ▶ 5-year Commercial Agreement – US\$0.6M
- ▶ Monthly subscription and future fee per scan revenues
- ▶ 5 Hospitals, cardiovascular centres, 30 practices
- ▶ Live in clinical workflow – PACS + EMR

*...we believe Artrya's Salix<sup>®</sup> platform with its AI-powered, user friendly and near real-time outcomes, provides our clinicians with another key tool to help detect heart disease earlier and save lives*

- Loy Howard, President and CEO of Tanner Health

## Next U.S. launch partners

- ▶ Cone Health and Northeast Georgia Health System have been key U.S. validation partners since 2024
- ▶ Work underway to integrate and go live shortly
- ▶ Each will also execute a Commercial Agreement
- ▶ U.S. launch partners – medium sized hospitals all moving to CCTA scans as first line test for patients with symptoms of coronary artery disease

# Flagship Novel Plaque Study – SAPPHIRE

Salix-based Analysis of Plaque to identify Patients at Higher Risk of Events

**The SAPPHIRE study will validate the novel Salix plaque analysis to identify patients at risk of heart attack and improve treatment.**

## Overview of Study

- 6 - 8 high volume U.S. Centres
- **Mass General, Ascension, Piedmont Healthcare** and **Huntsville Heart Centre** confirmed
- 3-phased retrospective study
- **Phase 1:** identify patients at risk using Salix Plaque analysis compared to current standard of care.  
Anticipated timeline – 12 months
- **Phase 2:** leverage Salix Plaque Dispersion Score to further risk stratify patients and change treatment.  
Anticipated timeline – 12 months

## Benefits

1. Predict future adverse events and improve treatment.
2. Build clinical awareness and credibility in US
3. Accelerate commercial adoption in US hospitals

# Key Takeaways

Salix<sup>®</sup> has moved from R&D to commercial use, and a structured pathway for U.S. expansion.

- 1 | Commercialisation activities and platform now scaling.
- 2 | Large growing market in the U.S. with established reimbursement codes
- 3 | Salix<sup>®</sup> platform live in the U.S. – generating revenues with a clear pathway to grow.
- 4 | FDA clearance of Salix<sup>®</sup> Coronary Plaque module driving increased revenue opportunity.  
Salix<sup>®</sup> Coronary Flow strengthens future market opportunity once FDA cleared
- 5 | Structured go-to-market approach into the U.S. market with 3 partners and SAPPHERE Study

[www.artrya.com](http://www.artrya.com)

### Corporate Enquiries

**John Konstantopoulos**

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

### Investor & Media Enquiries

**David Allen or John Granger**

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)

